Wnt/β-catenin signaling pathway in the tumor progression of adrenocortical carcinoma
Adrenocortical carcinoma (ACC) is an uncommon, aggressive endocrine malignancy with a high rate of recurrence, a poor prognosis, and a propensity for metastasis. Currently, only mitotane has received certification from both the US Food and Drug Administration (FDA) and the European Medicines Agency...
Main Authors: | Yanghao Tai, Jiwen Shang |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2024-01-01
|
Series: | Frontiers in Endocrinology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fendo.2023.1260701/full |
Similar Items
-
A reappraisal of transcriptional regulation by NR5A1 and beta-catenin in adrenocortical carcinoma
by: Enzo Lalli, et al.
Published: (2023-12-01) -
Empagliflozin improves pressure-overload-induced cardiac hypertrophy by inhibiting the canonical Wnt/β-catenin signaling pathway
by: Xun Yuan, et al.
Published: (2024-11-01) -
Mortalin promotes the evolution of androgen-independent prostate cancer through Wnt/β-catenin signaling pathway
by: Ying Chang, et al.
Published: (2024-06-01) -
Interaction between Wnt/β-catenin signaling pathway and EMT pathway mediates the mechanism of sunitinib resistance in renal cell carcinoma
by: Fangzhen Cai, et al.
Published: (2024-02-01) -
Wnt/β-catenin signaling pathway: an attractive potential therapeutic target in osteosarcoma
by: Yi Ding, et al.
Published: (2025-02-01)